Biotechnology company Moderna and pharmaceutical company, Medison Pharma, have announced a new agreement to commercialize the Moderna COVID-19 Vaccine across Central Eastern Europe and Israel.
Under the agreement, Medison will have distribution rights in Hungary and 19 other countries (Poland, Czech Republic, Romania, Bulgaria, Slovenia, Slovakia, Croatia, Estonia, Latvia, Lithuania, Serbia, Ukraine, Moldova, Albania, Bosnia and Herzegovina, Kosovo, Northern Macedonia, Montenegro, and Israel).
“We appreciate this new partnership with Medison Pharma to ensure successful delivery of our mRNA COVID-19 vaccine to market,” said Corinne Le Goff, Pharm.D., M.B.A., Chief Commercial Officer of Moderna.
“Working together with our partners, we remain steadfast in our commitment to fighting the pandemic by delivering our vaccine to populations globally.”
The Hungarian government had previously ordered rather limited quantities of Moderna’s coronavirus vaccine. At the time, the decision was justified on the grounds that Moderna was more expensive than other vaccines. The government later announced that no additional orders of the vaccine would be placed as there are already enough at hand in the country.
Currently, Covid-19 vaccines are only available in national reserves, but with the country’s growing stock of coronavirus vaccines, this will likely change in the future.
Featured photo illustration by Tibor Rosta/MTI